-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYP-001 in Respiratory Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYP-001 in Respiratory Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYP-001 in Respiratory Failure Drug Details: CYP-001 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BNT-321 in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-321 in Metastatic Adenocarcinoma of The Pancreas Drug Details:...
-
Product Insights
Respiratory Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Failure - Drugs In Development, 2023’, provides an overview of the Respiratory Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Arrhythmias – Drugs In Development, 2023
Global Markets Direct’s, ‘Arrhythmias - Drugs In Development, 2023’, provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Kidney Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Kidney Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Critical Limb Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Critical Limb Ischemia - Drugs In Development, 2023’, provides an overview of the Critical Limb Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Myocardial Infarction – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Infarction - Drugs In Development, 2023’, provides an overview of the Myocardial Infarction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...